
Diffuse Low-Grade Gliomas in Adults

Hugues Duffau
Editor

Diffuse Low-Grade Gliomas in Adults

Natural History, Interaction
with the Brain, and New
Individualized Therapeutic
Strategies

 Springer

Editor

Hugues Duffau, MD, PhD
Doctor Honoris Causa
Department of Neurosurgery
Gui de Chauliac Hospital
INSERM 1051
Institute for Neurosciences of
Montpellier
Montpellier University Medical Center
Montpellier
France

ISBN 978-1-4471-2212-8 ISBN 978-1-4471-2213-5 (eBook)
DOI 10.1007/978-1-4471-2213-5
Springer London Heidelberg New York Dordrecht

Library of Congress Control Number: 2013934834

© Springer-Verlag London 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Foreword

When it is all said and done, this will be the definitive source on diffuse low-grade gliomas and will serve as a comprehensive textbook for all clinicians and health-care providers who take care of patients with this disorder. What makes this book so unusual is the individualized personal approach to this problem on a patient-by-patient basis. In other words, one size does not fit all when it comes to diffuse low-grade gliomas. The approach the authors have taken in defining this entity and the options for management are quite unique and innovative, to say the least. We have come full circle in the way in which we approach this disease from a “wait-and-see” attitude to a more proactive individualized treatment regime based upon the dynamics of the lesion as seen preoperatively and the individualized approach to surgery and therapy which has influenced the outcome of this disease over the past decade.

The book is organized in a very logical and informative fashion, starting off with several chapters on epidemiology and pathological classification. There has been a significant evolution of our thought processes on the gliomagenesis of these lesions as well as its molecular profile, and therefore to truly understand how best to manage a patient with a diffuse low-grade glioma, one has to know the distinct patterns that exist in molecular classification for each patient. In other words, it is simply not acceptable anymore to classify a tumor based on histology without knowing the genotypic expression profile of the tumor. Further depth is developed in chapters devoted to the cellular origin of this lesion and the possible relationship this tumor has with stem cells or progenitors from different regions of the brain. While some of the chapters involving genomics do overlap, I particularly enjoyed reading the different ways in which this information is expressed and interpreted. Other particularly useful contributions include the role of proteomic classification, including a bioinformatic approach linking classification to outcome, as well as chapters involving cell cultures and animal models. To date, there have been very few cell cultures established for low-grade gliomas and, for that matter, appropriate animal models. However, it is clear that xenografts do exist, as do genetically engineered mouse models based upon certain types of phenotypic backgrounds. Overall, I found the basic science components of this textbook to be extraordinarily revealing, very thorough, and quite easy to read and apply to a given patient’s tumor.

The clinical aspects of this entity are further evolved in chapters on imaging, clinical presentation, and quality of life issues. The imaging is particularly valuable in that all aspects are covered, from anatomical imaging with

MRI to physiological imaging involving MRI and metabolic imaging with PET scanning. All of this information is woven together in subsequent chapters that develop predictive models based upon growth rates and invasion along white matter tracts to understand what the natural history of this disease will be likely to demonstrate. A particularly important contribution is that by Dr. Soffietti who explains in great detail various prognostic factors that influence the natural history and therefore define the risk of the disease as it affects the patient. This is done in such a way that incorporates all of the molecular biology, imaging, and clinical factors to enable the clinician to predict outcome and progression for a given patient's diffuse low-grade glioma.

Subsequent contributions apply to the functional assessment of various brain regions involved with these types of tumors. We all realize that language and cognition are so important to understand in terms of deciding how best to manage a patient and what to expect with the treatment strategy that we select for that given individual. Thus, bringing together some of the functional imaging modalities that we have, such as fMRI and MEG along with connectivity maps, allows us to be able to predict how language and cognition could be affected with surgery as well as various treatment options.

Clearly, surgery remains the most important treatment modality for this lesion, and thus, the chapters by Duffau and colleagues on surgery and functional considerations are extremely valuable in terms of planning any operative procedure with a lesion of this type. Dr. Duffau has one of the greatest experiences in the world in operating on diffuse low-grade gliomas, and he explains in great detail how to consider not only the anatomy but the function as mapped intraoperatively and how this influences the outcome of the patient. Great insight is given to how stimulation mapping can be used to decrease permanent deficits, making surgery for some of these complicated lesions quite safe. As he states so nicely, the surgeon has to adapt the surgical strategy to the anatomy and function of the brain done under awake conditions to maximize the extent of resection while minimizing morbidity. Another chapter is devoted to the oncological considerations of extensive resections and how important this is in not only affecting progression free survival but overall survival and malignant transformation.

Following surgery, adjuvant modalities are necessary in certain circumstances when residual disease remains. Excellent contributions are made in the areas of chemotherapy and radiation and how and when some of these modalities should be used. Several innovative strategies are also described, such as the use of chemotherapy performed preoperatively to reduce the volume of the mass, thus making so-called inoperable lesions quite operable. In fact, even patients with gliomatosis may become surgical candidates if they respond appropriately to chemotherapy. In addition, in the postoperative setting, one has to consider the use of functional rehabilitation as a means to improve the outcome of the patient and expedite relearning of functions that may be temporarily lost or compromised. This brings into consideration the concept of neuroplasticity and reorganization, which we know exists and, through a number of writings from Dr. Duffau, has shown all of us that areas thought to be functional can lose their functionality over time with chronically based lesions in so-called eloquent areas.

When reading this textbook, one cannot ignore the fact that we as clinicians must find new endpoints and look at different strategies for how this disease progresses and how it should be managed. We all recognize that there have to be better endpoints than time to progression or malignant transformation. We also have to consider clinical issues, such as the time it takes to return to a normal quality of life and functional status as equally important to the more standard endpoints used previously.

This is exactly why this book represents a more personalized approach to patients with diffuse low-grade gliomas. New strategies must be considered that take into consideration the concept of plasticity, which allows function to leave given areas and provides the surgeon the opportunity to remove what was once thought to be inoperable. The theme of this book, in terms of an individualized approach to a patient with a diffuse low-grade glioma, lets us think about different concepts such as allowing plasticity to help us shape the course of this disease and its treatment. We also need to think about the use of neoadjuvant therapy to shrink the tumor with chemotherapy and to first understand the growth kinetics of the lesion prior to just operating at the initial diagnosis. All of these factors contribute to the personalized approach, as explained throughout this textbook, to this lesion. I also like the concept of a supratotal resection, in which the goal with all of these functional considerations is to operate, not on the anatomy but to remove the lesion and a significant margin, as function permits, around the lesion. This will enable us to once again change the approach in an individualized way to the patient who has this maximal extent of resection. So far, the data seems quite convincing that patients who have these more aggressive supratotal resections might have a lower risk of malignant transformation, thus enabling surgery to change the natural history of the disease.

All in all, this is a major contribution that will be significant in the history of neurosurgery and neuro-oncology as it pertains to patients with diffuse low-grade gliomas. We cannot think in traditional terms any more about how to manage this disease. We have to employ the new strategies and concepts as described throughout this textbook to better individualize the approach to a given patient, therefore making more of an impact in the long run. I thoroughly enjoyed reading this book, and without a doubt, if you only have one reference source on diffuse low-grade gliomas, this must be it!

San Francisco, CA

Mitchel S. Berger, MD

Contents

1 Introduction: From the Inhibition of Dogmas to the Concept of Personalized Management in Diffuse Low-Grade Gliomas.	1
Hugues Duffau	
Part I Epidemiology and Classification	
2 Epidemiology of Diffuse Low-Grade Gliomas	9
Luc Bauchet	
3 Histological Classification	31
Valérie Rigau	
4 Is Gliomatosis Cerebri a Diffuse Low-Grade Glioma?	45
Catherine Godfraind	
5 Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma.	61
Hiroko Ohgaki	
Part II Basic Science and Experimental Research in DLGG	
6 Cellular Origin of Grade II Gliomas	75
Pierre-Olivier Guichet and Jean-Philippe Hugnot	
7 Deciphering the Molecular and Cellular Basis for Dissemination of Diffuse Low-Grade Gliomas	91
Zahra Hassani and Jean-Philippe Hugnot	
8 The Molecular Biology of Diffuse Low-Grade Gliomas.	99
Nicholas F. Marko and Robert J. Weil	
9 Proteomic Studies in Low-Grade Gliomas: What Have They Informed About Pathophysiology?	117
A.M.J. Gerth, R.F. Deighton, J. McCulloch, and Ian R. Whittle	
10 Human Low-Grade Glioma Cultures	137
Daniela Cesselli, Antonio Paolo Beltrami, Anja Pucer, Evgenia Bourkoula, Tamara Ius, Marco Vindigni, Miran Skrap, and Carlo Alberto Beltrami	

11	Animal Models for Low-Grade Gliomas	165
	Rolf Bjerkvig, Sébastien Bougnaud, and Simone P. Niclou	
Part III Clinical Aspects and Diagnostic Imaging		
12	Clinical Presentation in Diffuse Low-Grade Gliomas	179
	Juan Torres-Reveron, Joseph M. Piepmeier, and Kevin P. Becker	
13	Epilepsy in Diffuse Low-Grade Gliomas	189
	Anja Smits	
14	Quality of Life in Low-Grade Gliomas	205
	Martin J.B. Taphoorn	
15	Metabolic-Oncological MR Imaging of Diffuse Low-Grade Glioma: A Dynamic Approach.	219
	Rémy Guillevin	
16	Positron Emission Tomography in Diffuse Low-Grade Gliomas.	235
	Karl-Josef Langen, Frank Willi Floeth, Michael Sabel, and Norbert Galldiks	
17	Dynamics of DLGG and Clinical Implications	249
	Emmanuel Mandonnet	
Part IV Natural History and Spontaneous Prognostic Factors		
18	Natural History and Spontaneous Prognostic Factors	265
	Roberta Rudà, Luca Bertero, and Riccardo Soffietti	
Part V Functional Assessment and Interaction with the Brain		
19	Language and Other Cognitive Evaluations	279
	Sylvie Moritz-Gasser and Guillaume Herbet	
20	Functional MR and Diffusion MR Imaging in Diffuse Low-Grade Gliomas.	301
	Alberto Bizzi	
21	Magnetoencephalography, Functional Connectivity, and Neural Network Topology in Diffuse Low-Grade Gliomas.	321
	Jan J. Heimans, Jaap C. Reijneveld, and Cornelis J. Stam	
22	Interactions Between Diffuse Low-Grade Glioma (DLGG) and Brain Plasticity	337
	Hugues Duffau	

Part VI New Insights into the Therapeutic Strategies for DLGG

23	Surgery for Diffuse Low-Grade Gliomas (DLGG) Oncological Considerations	359
	Hugues Duffau	
24	Surgery for Diffuse Low-Grade Gliomas (DLGG) Functional Considerations	375
	Hugues Duffau	
25	Chemotherapy for Diffuse Low-Grade Gliomas	401
	Luc Taillandier	
26	Radiation Therapy for the Treatment of Diffuse Low-Grade Gliomas	423
	Stephanie E. Combs	
27	New Individualized Strategies in DLGG	435
	Hugues Duffau and Luc Taillandier	

Part VII Prospects

28	Biomathematical Modeling of DLGG Behavior	447
	Emmanuel Mandonnet	
29	Toward the Definition of New Endpoints	457
	Emmanuel Mandonnet, Luc Bauchet, Luc Taillandier, and Hugues Duffau	
30	Functional Rehabilitation in Patients with Diffuse Low-Grade Glioma (DLGG)	463
	Guillaume Herbet and Sylvie Moritz-Gasser	
31	Early Detection and Management of Incidental Diffuse Low-Grade Gliomas (IDLGG): Toward a “Prophylactic Oncological Neurosurgery”	475
	Hugues Duffau	
32	The Origins of Diffuse Low-Grade Gliomas (DLGGs): “Functional Theory” Versus “Molecular Theory”	481
	Catherine Gozé, Luc Taillandier, Valérie Rigau, Luc Bauchet, and Hugues Duffau	
	Index	493

Contributors

Mitchel S. Berger, MD Department of Neurosurgery, University of California at San Francisco, San Francisco, CA, USA

Luc Bauchet, MD, PhD Institute for Neurosciences of Montpellier, Team “Brain Plasticity, Stem Cells and Glial Tumors”, National Institute for Health and Medical Research (INSERM), Montpellier University Medical Center, Montpellier, France

Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France

French Brain Tumor DataBase, Groupe de Neuro-Oncologie du Languedoc-Roussillon, Registre des Tumeurs de l’Hérault, Centre de Lutte Contre le Cancer Val d’Aurelle, Montpellier, France

Kevin P. Becker, MD, PhD Department of Neurology, School of Medicine, Yale University, New Haven, CT, USA

Antonio Paolo Beltrami, MD, PhD Interdepartmental Center for Regenerative Medicine, University of Udine, Udine, Italy

Department of Medical and Biological Sciences, University of Udine, Udine, Italy

Department of Pathology, Azienda Ospedaliero Universitaria di Udine, Udine, Italy

Carlo Alberto Beltrami Interdepartmental Center for Regenerative Medicine, University of Udine, Udine, Italy

Department of Medical and Biological Sciences, University of Udine, Udine, Italy

Department of Pathology, Azienda Ospedaliero Universitaria di Udine, Udine, Italy

Luca Bertero, MD Division of Neuro-Oncology, Departments of Neuroscience and Oncology, University and San Giovanni Battista Hospital, Turin, Italy

Alberto Bizzi, MD Department of Neuroradiology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy

Rolf Bjerkvig, PhD NorLux Neuro-Oncology Laboratory,
Department of Oncology, Centre de Recherche Public de la
Santé (CRP-Santé), Luxembourg City, Luxembourg

NorLux Neuro-Oncology Laboratory, Department of Biomedicine,
University of Bergen, Bergen, Norway

Sébastien Bourgnaud NorLux Neuro-Oncology Laboratory,
Department of Oncology, Centre de Recherche Public de la
Santé (CRP-Santé), Luxembourg City, Luxembourg

Evgenia Bourkoula Interdepartmental Center for Regenerative
Medicine, University of Udine, Udine, Italy

Department of Medical and Biological Sciences, University
of Udine, Udine, Italy

Department of Pathology, Azienda Ospedaliero Universitaria
di Udine, Udine, Italy

Daniela Cesselli, MD, PhD Interdepartmental Center for
Regenerative Medicine, University of Udine, Udine, Italy

Department of Medical and Biological Sciences, University
of Udine, Udine, Italy

Department of Pathology, Azienda Ospedaliero Universitaria
di Udine, Udine, Italy

Stephanie E. Combs, MD Department of Radiation Oncology,
University Hospital of Heidelberg, Heidelberg, Germany

R.F. Deighton Centre for Cognitive and Neural Systems,
University of Edinburgh, Edinburgh, UK

Division of Clinical Neurosciences, University of Edinburgh,
Western General Hospital, Edinburgh, UK

Hugues Duffau, MD, PhD Doctor Honoris Causa, Department of
Neurosurgery, Gui de Chauliac Hospital, Montpellier University
Medical Center, Montpellier, France

Institute for Neurosciences of Montpellier, Team “Brain Plasticity, Stem
Cells and Glial Tumors”, National Institute for Health and Medical
Research (INSERM), Montpellier, France

Frank Willi Floeth Department of Spine and Pain,
St.-Vinzenz-Hospital, Düsseldorf, Germany

Norbert Galldiks, MD INM-3: Cognitive Neuroscience,
Institute of Neuroscience and Medicine, Forschungszentrum Jülich,
Jülich, Germany

Department of Neurology, University Hospital Cologne,
Cologne, Germany

A.M.J. Gerth Centre for Clinical Brain Science, Western General Hospital, University of Edinburgh, Edinburgh, UK

Centre for Cognitive and Neural Systems, University of Edinburgh, Edinburgh, UK

Catherine Godfraind, MD, PhD Department of Pathology, Cliniques Universitaires Si-Luc, Brussels, Belgium

Catherine Gozé, PharmD, PhD Department of Cellular Biology, Montpellier University Medical Center, Montpellier, France

Institute for Neurosciences of Montpellier, Team “Brain Plasticity, Stem Cells and Glial Tumors”, Montpellier University Medical Center, Montpellier, France

Pierre-Olivier Guichet INSERM U1051, Institute for Neuroscience of Montpellier, Hopital Saint Eloi, Montpellier, France

Rémy Guillevin, MD, PhD Department of Radiology and MPIM Laboratory, Teaching Hospital, University of Poitiers, Poitiers, France

Functional Laboratory Imaging, Neuroradiology Department, Teaching Hospital, University of Poitiers, Poitiers, France

Zahra Hassani, PhD INSERM U1051, Université Montpellier 2, Institute for Neurosciences of Montpellier, Hôpital Saint Eloi, Montpellier, France

Team “Brain Plasticity, Stem Cells and Glial Tumor”, UM2-UM1-INSERM U1051, Institute of Neurosciences of Montpellier, Montpellier, France

Jan J. Heimans, MD, PhD Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands

Guillaume Herbet National Institute for Health and Medical Research (INSERM), U1051, Team “Plasticity of the Central Nervous System, Human Stem Cells and Glial Tumors”, Institute for Neurosciences of Montpellier, Montpellier University Medical Center, Montpellier, France

Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France

Jean-Philippe Hugnot, PhD INSERM U1051, Université Montpellier 2, Institute for Neuroscience of Montpellier, Hopital Saint Eloi, Montpellier, France

Team “Brain Plasticity, Stem Cells and Glial Tumor”, UM2-UM1-INSERM U1051, Institute of Neurosciences of Montpellier, Montpellier, France

Tamara Ius, MD Department of Neurosurgery, Azienda Ospedaliero Universitaria di Udine, Udine, Italy

Karl-Josef Langen, MD INM-4: Medical Imaging Physics,
Institute of Neuroscience and Medicine, Forschungszentrum Jülich,
Jülich, Germany

Emmanuel Mandonnet, MD, PhD Department of Neurosurgery,
Lariboisière Hospital, Paris, France

Nicholas F. Marko, MD Department of Neurosurgery, University of Texas
MD Anderson Cancer Center, Houston, USA

J. McCulloch Centre for Cognitive and Neural Systems,
University of Edinburgh, Edinburgh, UK

Sylvie Moritz-Gasser National Institute for Health and Medical
Research (INSERM), U1051, Team “Plasticity of the Central
Nervous System, Human Stem Cells and Glial Tumors”, Institute
for Neurosciences of Montpellier, Montpellier University
Medical Center, Montpellier, France

Department of Neurology, CHRU Montpellier, Gui de Chauliac
Hospital, Montpellier University Medical Center, Montpellier, France

Simone P. Niclou, PhD NorLux Neuro-Oncology Laboratory,
Department of Oncology, Centre de Recherche Public de la
Santé (CRP-Santé), Luxembourg City, Luxembourg

Hiroko Ohgaki, PhD Section of Molecular Pathology,
International Agency for Research on Cancer (IARC), Lyon, France

Joseph M. Piepmeier, MD Department of Neurosurgery,
School of Medicine, Yale University, New Haven CT, USA

Anja Pucer, PhD Interdepartmental Center for Regenerative
Medicine, University of Udine, Udine, Italy

Department of Medical and Biological Sciences, University
of Udine, Udine, Italy

Department of Pathology, Azienda Ospedaliero Universitaria
di Udine, Udine, Italy

Jaap C. Reijneveld, MD, PhD Department of Neurology,
VU University Medical Center, Amsterdam, The Netherlands

Valérie Rigau, MD, PhD Cytology and Anatomical Pathology Laboratory,
Montpellier University Medical Center, Montpellier, France

Team “Neuronal Death and Epilepsia”, CNRS UMR 5203 INSERM U661
UM1-UM2, Montpellier, France

Roberto Rudà, MD Division of Neuro-Oncology, Departments
of Neuroscience and Oncology, University and San Giovanni Battista
Hospital, Turin, Italy

Michael Sabel, MD Department of Neurosurgery,
Heinrich-Heine-University, Düsseldorf, Germany

Miran Skrap, MD Department of Neurosurgery, Azienda
Ospedaliero Universitaria di Udine, Udine, Italy

Anja Smits, MD, PhD Department of Neuroscience,
Neurology Uppsala University, Uppsala, Sweden

Riccardo Soffietti, MD Division of Neuro-Oncology, Departments
of Neuroscience and Oncology, University and San Giovanni Battista
Hospital, Turin, Italy

Cornelius J. Stam, MD, PhD Department of Clinical
Neurophysiology, VU University Medical Center, Amsterdam,
The Netherlands

Luc Taillandier, MD, PhD Neurooncology Unit, Department of
Neurology, Nancy University Medical Center, Nancy, France

Martin J.B. Taphoorn, MD, PhD Department of Neurology,
VU University Medical Center, Amsterdam, The Netherlands

Department of Neurology, Medical Center Haaglanden, The Hague,
The Netherlands

Juan Torres-Reveron, MD, PhD Department of Neurosurgery,
School of Medicine, Yale University, New Haven, CT, USA

Marco Vindigni, MD Department of Neurosurgery, Azienda
Ospedaliero Universitaria di Udine, Udine, Italy

Robert J. Weil, MD Department of Neurosurgery, Brain Tumor
and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA

Ian R. Whittle, MD, PhD Division of Clinical Neurosciences,
University of Edinburgh, Western General Hospital, Edinburgh, UK

Department of Clinical Neurosciences, Western General Hospital,
Edinburgh, Scotland, UK